Crohn’s disease can be described as an inflammatory disease of the bowel and gastrointestinal (GI) tract. As opined by Market Research Future (MRFR), the global Crohn’s disease market overview is expected to register a CAGR of over 3.3% over the assessment period (2016-2025). Growing treatment intensity and incidence of Crohn’s disease is the prime driver of the market.
The growing exposure to risk factors such as smoking, the use of antibiotics and nonsteroidal anti-inflammatory drugs is triggering a large incidence of Crohn’s disease. According to the latest data, almost 1.6 million U.S. citizens suffer from inflammatory bowel disease compared to 200,000 patients in 2011. The high remission and relapse rate of 50% and 35% for Crohn’s disease is another driver of market growth. Almost 11% of patients have chronic Crohn’s disease. The incidence of Crohn’s disease was 10.7 per 100,000, or almost 33,000 new cases each year. Extrapolating the data yields an approximate patient pool of 780,000 U.S. citizens.
The identification of genetic mutations associated with Crohn’s disease is driving a large research and development expenditure. Additional factors that are fostering the market demand include the growing per capita income and the low elasticity of treatment. However, the poor outcome of treatment owing to the lack of curative treatment is hampering the Crohn's disease market. Most treatment is symptomatic aimed to prevent relapse.
Request Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/2344
Global Crohn’s disease market overview – Segments
The report covers three dynamics and inspires better understanding,
By Type : Ileocolitis, Ileitis, Granulomatous Colitis, Gastroduodenal Crohn’s Disease, Jejunoileitis, Perianal Crohn’s Disease, among others.
By Treatment : Non-Surgical (Corticosteroids, Oral 5-Aminosalicylates, Azathioprine, Mercaptopurine, TNF Inhibitors, Methotrexate, Natalizumab, Vedolizumab, Ustekinumab, Anti-Inflammatory, Immune System Suppressors, Antibiotics, Others) and Surgical.
By End User : Hospitals & Clinics, Research Institutes, Diagnostic Centres, Others.
By Regions : North America, Europe, Asia Pacific, and Middle East & Africa.
Global Crohn’s disease market overview – Regional Analysis
North America dominates the global Crohn’s disease market overview owing to large healthcare expenditure, prosperous baby boomers’ population and the presence of excellent healthcare infrastructure. Initiatives by government bodies for the development of new drug molecules and public funding for drug development such as the American Gastroenterological Association (AGA), partnership with Pfizer, is expected to drive a large research and development enthusiasm. The growing number of grants for encouraging research in inflammatory bowel diseases (IBD) is driving large players to engage their expertise for the development of novel drug molecules.
Crohn’s disease market overview in Europe is driving a large growth owing to excellent reimbursement, greater hospitalization rates, and high per capita income. The incidence of Crohn disease in Europe is approximately 5. 6 per 100,000.
The Asia Pacific Crohn’s disease market is projected to emerge as a lucrative region owing to a large patient pool. However, the lower incidence of Crohn’s disease in developing regions coupled with the low per capita healthcare expenditure is hampering the market growth.
The markets in the Middle East and Africa are expected to grow at a fast rate owing to a large untreated patient pool generating a large unmet demand.
Global Crohn’s disease market overview – Competitive Landscape
The Crohn’s disease market overview is highly fragmented and competitive due to the presence of several big and small players. Lack of curative treatment is the Achilles heel of the market and most treatment is symptomatic with no market exclusivity. Thus, new drug development is the only viable long-term strategy.
Manufacturers rely on research and development collaboration and partnerships with other players to reduce the new drug development risk. Research grants are another approach that has the potential to reduce the developmental cost. Sharing of expertise between players may reduce the uncertainty associated with new drug development. The market will rapidly adopt any new drug with a partial curative property with minimal marketing costs and efforts.
Major Players:
Players leading the global Crohn’s disease market include Bayer AG, Johnson & Johnson Services Inc., UCB S.A., Pfizer Inc., AbbVie Inc, Amgen, Inc., Takeda Pharmaceutical Company Limited, Ferring B.V., Allergan, Eli Lilly and Company, Bristol-Myers Squibb, Hoffman-La Roche, among others.
Industry/ Innovation/ Related News:
May 22, 2019---- Takeda Pharmaceutical Company Limited received approval from the Ministry of Health, Labour and Welfare (MHLW) for an additional indication for Entyvio (vedolizumab). Entyvio received Japan's approval for the treatment of adults suffering from moderate to severe Crohn’s disease. Entyvio was before approved in Japan in 2018 for the treatment of ulcerative colitis.
The approval was granted after the success of Study CCT-001, aimed at investigating the efficacy, and safety of vedolizumab maintenance treatment in Crohn’s disease in addition to the success of the GEMINI 2 and 3 trials. Entyvio is a biologic drug with a novel mechanism of action that selectively regulates the immune response in the gut.
Browse Detailed TOC with COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/crohns-disease-market-2344
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: [email protected]
